Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Journal Articles

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 287.

https://doi.org/10.1182/blood-2024-202589

Published: 2024

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Meghan Sise, Elizabeth Shelton, Emily Simone, Naomi Sender, Sherley Mejia, Shayan Shirazayan

Blood (2024) 144 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2024-210308

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, J Christine Ye, Samuel M. Rubinstein, Sascha Tuchman, Eben I Lichtman

Blood (2024) 144 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2024-210587

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Michael Sang Hughes, Metodi Balev, Jai Radhakrishnan, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2024) 144 (Supplement 1): 6983.

https://doi.org/10.1182/blood-2024-209301

Published: 2024

Journal Articles

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

George Mellgard, Molly Gilligan, Edward R Scheffer Cliff, Divaya Bhutani, Ghulam Rehman Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2023) 142 (Supplement 1): 4768.

https://doi.org/10.1182/blood-2023-174908

Published: 2023

Journal Articles

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Michael Sang Hughes, Siyang Leng, Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Shahzad Raza, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6576.

https://doi.org/10.1182/blood-2023-182842

Published: 2023

Journal Articles

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Rajshekhar Chakraborty, Divaya Bhutani, Markus Mapara, Ran Reshef, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2023-187214

Published: 2023

Journal Articles

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Daniel T Peters, Jacob Amburn, Sascha Tuchman, Eben I Lichtman, Christopher Edward Jensen, Koyal Jain, Suzanne Lentzsch, Rajshekhar Chakraborty, Divaya Bhutani, Samuel M Rubinstein

Blood (2023) 142 (Supplement 1): 2027.

https://doi.org/10.1182/blood-2023-189341

Published: 2023

Journal Articles

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

Blood (2023) 142 (Supplement 1): 545.

https://doi.org/10.1182/blood-2023-174875

Published: 2023

Journal Articles

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Kara I. Cicero, Alfred I. Neugut, Andrew H. Doyle, Divaya Bhutani, Amer Assal, Ran Reshef, Markus Y. Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2022) 140 (Supplement 1): 8026–8027.

https://doi.org/10.1182/blood-2022-166491

Published: 2022

Journal Articles

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Camille Vanessa Edwards, Nisha Rao, Divaya Bhutani, Markus Mapara, Jai Radhakrishnan, Sofia Shames, Mathew S. Maurer, Siyang Leng, Alan Solomon, Suzanne Lentzsch, Andrew Eisenberger

Blood (2021) 138 (25): 2632–2641.

https://doi.org/10.1182/blood.2020009039

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis

Madeleine Hopson, Divaya Bhutani, Shawn M Sarkaria, Mathew Maurer, Jan Griffin, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2021) 138 (Supplement 1): 4726.

https://doi.org/10.1182/blood-2021-149299

Published: 2021

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Erlene K. Seymour, MD, Yiwei Li, Amro Aboukameel, Radhakrishnan Ramchandren, Golbon Sterbis, Jay Yang, MD, Divaya Bhutani, MD, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, Jeff Zonder, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140752

Published: 2020

Journal Articles

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD, Ryan C. Lynch, MD, Aakash Desai, MD, Catherine Stratton, MPH, Alokkumar Jha, PhD, Ziad Bakouny, MD MSc, Andrew Schmidt, MD, R. Alejandro Sica, MD, Divaya Bhutani, MD, Dimpy P. Shah, MD PhD, Sarah A Wall, MD, Gary H. Lyman, MD, Nicole M. Kuderer, MD MSc, Matthias Weiss, MD PhD, Jeremy L. Warner, MD MS, Keith E. Stockerl-Goldstein, MD, Ruben Mesa, MD, Michael A. Thompson, MD PhD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-141937

Published: 2020

NARROW

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Isatuximab for Treatment of Monoclonal Gammopathy of Renal Significance (MGRS) - Results from a Prospective Phase 2 Trial

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Outcomes of Therapy of Monoclonal Gammopathy of Renal Significance (MGRS)

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Proteinuria with Preserved Renal Function: A Retrospective Cohort Study of Myeloma Patients with Significant Proteinuria without Acute Kidney Injury

Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM)

Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up

Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program

Outcomes Associated with Clone-Directed Therapies for Monoclonal Gammopathy of Renal Significance

Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study

The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis

Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only